



Universiteit  
Leiden  
The Netherlands

## Novel pharmaceutical interventions in experimental atherosclerosis and myocardial infarction

Hoorn, Johanna Wijnanda Anthonia van der

### Citation

Hoorn, J. W. A. van der. (2008, October 30). *Novel pharmaceutical interventions in experimental atherosclerosis and myocardial infarction*. Retrieved from <https://hdl.handle.net/1887/13213>


Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/13213>

**Note:** To cite this publication please use the final published version (if applicable).

**NOVEL PHARMACEUTICAL INTERVENTIONS IN  
EXPERIMENTAL ATHEROSCLEROSIS AND  
MYOCARDIAL INFARCTION**



**Colophon**

© J.W.A. van der Hoorn, 2008. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any mean, without the prior written permission of the author.

**ISBN**

978-90-9023483-0

**Cover illustration**

© iStockphoto/Angellhell

**Printed by**

Drukkerij Haveka, Alblasserdam

The printing of this thesis was kindly supported by:

AB diets

Pfizer BV

AstraZeneca BV

Sanofi-Aventis BV

Boehringer Ingelheim BV

Servier BV

Bristol Myers Squibb BV

Siemens BV

Cordis - Johnson & Johnson

TNO Quality of Life

Merck Sharp and Dohme BV

Vakgarage Leo van der Hoorn

# **Novel Pharmaceutical Interventions in Experimental Atherosclerosis and Myocardial Infarction**

PROEFSCHRIFT

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden,

op gezag van Rector Magnificus prof.mr. P.F. van der Heijden,

volgens besluit van het College voor Promoties

te verdedigen op donderdag 30 oktober 2008

klokke 16.15 uur

door

**Johanna Wijnanda Anthonia van der Hoorn**

geboren te Woubrugge

in 1981

# Promotiecommissie

- Promotores:** Prof. Dr. J.W. Jukema  
Prof. Dr. Ir. L.M. Havekes
- Co-Promotor:** Dr. H.M.G. Princen
- Referent:** Prof. Dr. E.A.L. Biessen (Universiteit Maastricht)
- Overige leden:** Prof. Dr. A. van der Laarse  
Prof. Dr. G. Pasterkamp (Universiteit Utrecht)  
Prof. Dr. P.H.A. Quax  
Dr. P.C.N. Rensen

The studies presented in this thesis were performed at the Gaubius Laboratory of TNO Quality of Life, BioSciences, Leiden, The Netherlands. The work was in part financially supported by AstraZeneca, Sankyo-Daiichi, Sanofi-Aventis and Servier.

Financial support by the Netherlands Heart Foundation and the J.E. Jurriaanse Stichting for the publication of this thesis is gratefully acknowledged.

*“De moed erin houden en alles van de positieve kant bekijken”*

Oma Van der Hoorn (1912-2004)

# Table of contents

<b>CHAPTER 1</b>	<b>9</b>
General introduction	
<b>CHAPTER 2</b>	<b>25</b>
Amlodipine and Atorvastatin in Atherosclerosis: A review of the potential of combination therapy. <i>Expert Opin Pharmacother. 2004 Feb;5(2):459-68</i>	
<b>CHAPTER 3</b>	<b>45</b>
Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. <i>Arterioscl Thromb Vasc Biol, 2008 in press</i>	
<b>CHAPTER 4</b>	<b>65</b>
New cholesterol absorption inhibitor AVE5530 is more effective in preventing atherosclerosis than ezetimibe in APOE*3Leiden mice. <i>Submitted</i>	
<b>CHAPTER 5</b>	<b>79</b>
Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice. <i>J Hypertens. 2007 Dec;25(12):2454-62</i>	
<b>CHAPTER 6</b>	<b>95</b>
Dual PPAR $\alpha/\gamma$ agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. <i>Submitted</i>	
<b>CHAPTER 7</b>	<b>111</b>
On top of aggressive cholesterol lowering the thromboxane-prostanoid receptor antagonist S18886 (terutroban) blocks the progression of atherosclerosis in APOE*3Leiden transgenic mice. <i>Submitted</i>	

<b>CHAPTER 8</b>	<b>127</b>
Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE*3Leiden mice are prevented by combined treatment with thromboxane-prostanoid receptor antagonist S18886 (terutroban) <i>Crit Care Med 2008 Sep;36(9):2576-82</i>	
<b>CHAPTER 9</b>	<b>143</b>
General discussion and future perspectives	
<b>SUMMARY</b>	<b>153</b>
<b>SAMENVATTING</b>	<b>159</b>
<b>LIST OF PUBLICATIONS</b>	<b>165</b>
<b>CURRICULUM VITAE</b>	<b>169</b>



